Reasons overall and risk rates by application type of disease-modifying treatment for discontinuation for three time periods 2010–2012, 2013–2015 and 2016–2018
| Reasons for discontinuation, % | 10–12 | 13–15 | 16–18 |
| Antibodies/JCV-virus titre | 1.28 | 1.85 | 1.51 |
| family planning | 4.10 | 5.48 | 6.34 |
| Adverse events | 5.13 | 15.89 | 13.12 |
| Lack of effectiveness | 18.21 | 19.31 | 27.90 |
| Freedom of disease activity | NA | 0.34 | 0.36 |
| Non-medical reasons | 71.28 | 57.11 | 50.76 |
| Risk rates for discontinuation | |||
| Injectables | 0.59 | 0.54 | 0.33 |
| Orals | 0.39 | 0.36 | 0.21 |
| Infusions | 0.59 | 0.37 | 0.17 |
Non-medical reasons summarise patients’ perceptions and wishes.
JCV, John Cunningham Virus; NA, not applicable as criteria was not captured.